First program from the Topas platform to enter clinical testing PM203 is one of several proprietary programs being developed by Topas Pemphigus vulgaris is an orphan indication that currently has no cure Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural…
To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance…
Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects Exeed will mould and de-risk opportunities, making them ready for company creation and Series A investment Co-founder Dr. Henning Steinhagen appointed as CEO …
18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis Currently available anticoagulants carry high risk of bleeding Leeds, UK, 02 December 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused…